Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AddLife ABCHIX:ALIFBS 82 EV-to-OCF is 18.83 as of Sep. 18, 2026, which is 26% below its 10-year median of 25.34. GuruFocus rates CHIX:ALIFBS with a GF Score™ of 82/100 and a GF Value™ of kr150.01 (Fairly Valued). The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, AddLife AB ranks worse than 73.24% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, AddLife AB's Enterprise Value is kr24,520 Mil.
AddLife AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr1,302 Mil. Therefore, AddLife AB's EV-to-OCF for today is 18.83.
The historical rank and industry rank for AddLife AB's EV-to-OCF or its related term are showing as below:
CHIX:ALIFBs'
s EV-to-OCF Range Over the Past 10 Years
Min: 14.63 Med: 25.34 Max: 50.53
Current: 18.38
During the past 12 years, the highest EV-to-OCF of AddLife AB was 50.53. The lowest was 14.63. And the median was 25.34.
CHIX:ALIFBs's EV-to-OCF is ranked worse than 73.24% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 7.865
vs CHIX:ALIFBs: 18.38
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AddLife AB's share price for today is kr165.40.
AddLife AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr4.907.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
AddLife AB EV-to-OCF Related Terms
AddLife AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for AddLife AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALIFBS vs ISRG, BDX, RMD: EV-to-OCF Comparison
For the Medical Instruments & Supplies subindustry, AddLife AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AddLife AB EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AddLife AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where AddLife AB's EV-to-OCF falls into.
AddLife AB's current Enterprise Value is kr24,520 Mil.
AddLife AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,302 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AddLife AB (CHIX:ALIFBS) has a EV-to-OCF of 18.83 as of Sep. 18, 2026. This is 26% below median its historical median of 25.34. Over the past decade, AddLife AB's EV-to-OCF has ranged from 14.63 to 50.53. According to the industry distribution chart, AddLife AB ranks #624 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 73.2%.
Is AddLife AB's EV-to-OCF too high?
AddLife AB's current EV-to-OCF of 18.83 is 26% below median its 10-year median of 25.34. Over the past 10 years, this metric has ranged from a low of 14.63 to a high of 50.53. The Medical Devices & Instruments industry median EV-to-OCF is 7.87. AddLife AB's value of 18.83 is 139.4% above this industry median. Based on the distribution chart, AddLife AB ranks #624 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, AddLife AB has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AddLife AB's EV-to-OCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AddLife AB ranks #624 out of 852 companies for EV-to-OCF. This places AddLife AB in the lower half of its industry. The industry median EV-to-OCF is 7.87. AddLife AB's value of 18.83 is 139.4% above this benchmark. Historically, AddLife AB's own EV-to-OCF has ranged from 14.63 to 50.53 over the past decade. While the company's 10-year median is 25.34 vs. the industry median of 7.87, AddLife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.87, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AddLife AB's current EV-to-OCF of 18.83 is 139.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AddLife AB's current EV-to-OCF is 18.83, which is 26% below median its own 10-year median of 25.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AddLife AB stock overvalued right now?
Based on GuruFocus' analysis, AddLife AB (CHIX:ALIFBS) is currently considered Fairly Valued. The stock's GF Value™ is kr150.01, compared to a current price of kr165.40 — trading 10.3% above its estimated fair value. The current EV-to-OCF is 18.83, which is 26% below median its 10-year median of 25.34 and 139.4% above the Medical Devices & Instruments industry median of 7.87. AddLife AB's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For AddLife AB (CHIX:ALIFBS), the current EV-to-OCF is 18.83 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AddLife AB (CHIX:ALIFBS) Overvalued in 2026?
Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued.
The current stock price of kr165.40 is trading 10.3% above its estimated GF Value™ of kr150.01.
GuruFocus considers AddLife AB to be Fairly Valued.
Key valuation signals for CHIX:ALIFBS:
EV-to-OCF: 18.83 (26% below median its 10-year median of 25.34)
GF Value™: kr150.01 vs. price of kr165.40 (10.3% above fair value)
Industry Position: 139.4% above the Medical Devices & Instruments median (#624 of 852)
No single metric tells the full story. See the CHIX:ALIFBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
82GF Score
Get the complete analysis for CHIX:ALIFBS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALIFBS has been successfully added to your 
